Ceftolozane/tazobactam for hospital-acquired/ventilator-associated bacterial pneumonia due to ESBL-producing Enterobacterales: a subgroup analysis of the ASPECT-NP clinical trial.
David L PatersonMatteo BassettiMary MotylMatthew G JohnsonMariana CastanheiraErin H JensenJennifer A HuntingtonBrian YuDominik J WolfChristopher J BrunoPublished in: The Journal of antimicrobial chemotherapy (2022)
These data confirm ceftolozane/tazobactam as an effective treatment option for HABP/VABP involving ceftolozane/tazobactam-susceptible ESBL-positive and/or AmpC-producing Enterobacterales.
Keyphrases
- gram negative
- multidrug resistant
- klebsiella pneumoniae
- escherichia coli
- clinical trial
- healthcare
- electronic health record
- phase iii
- big data
- double blind
- randomized controlled trial
- emergency department
- acute care
- extracorporeal membrane oxygenation
- smoking cessation
- respiratory failure
- data analysis
- mechanical ventilation